m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer

• Published in: Theranostics 2020-01, Vol.10 (21), p.9528-9543
• Main Authors: Zhao, Qijie, Zhao, Yueshui, Hu, Wei, Zhang, Yan, Wu, Xu, Lu, Jianwei, Li, Mingxing, Li, Wei, Wu, Weiqing, Wang, Jianhong, Du, Fukuan, Ji, Huijiao, Yang, Xiao, Xu, Zhenyu, Lin, Wan, Wen, Qinglian, Li, Xiang, Cho, Chi Hin, Zou, Chang, Shen, Jing, Xiao, Zhangang
• Format: Article
• Language: English
• Subjects: Bioinformatics; Cancer; DNA methylation; Epigenetics; Gastrointestinal cancer; Gene expression; Genomes; Mammals; Medical prognosis; Phylogenetics; Proteins; Research Paper; Tumors
• ISSN: 1838-7640
• DOI: 10.7150/thno.42971

Rationale: Methylation at the N6 position of adenosine (m6A) is the most prevalent RNA modification within protein-coding mRNAs in mammals, and it is a reversible modification with various important biological functions. The formation and function of m6A are regulated by methyltransferases (writers), demethylases (erasers), and special binding proteins (readers) as key factors. However, the underlying modification mechanisms of m6A in gastrointestinal (GI) cancer remain unclear. Here, we performed comprehensive molecular profiling of the nine known m6A writer, eraser, and reader proteins in GI cancer. Methods: Data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were used. Gene alteration and pathway analysis were done in cBioportal. The protein network of m6A regulators and its related pathway members was analyzed in STRING online platform. Phylogenetic tree was constructed in MEGA7. m6A modification sites were predicted by SRAMP. m6A related SNPs were analyzed by m6ASNP. The modulation of m6A on its related pathway members was validated by m6A-seq, real-time PCR and phosphor-MAPK array. Results: We found that m6A regulators were mostly upregulated in GI cancer and their differential expression significantly influenced the overall survival of patients with GI cancer. The phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR) signaling pathways were found to be potentially affected by m6A modification in most human cancers, including GI cancer, which was further verified by m6A-Seq and phospho-MAPK array. Conclusions: Our findings suggest that m6A RNA modification has a fundamental role in the regulation of PI3K/Akt and mTOR signaling pathway function in cancer.